Magnolol and amorfrutin 2, structurally similar to cannabinoids but from non-cannabis plants, demonstrated antiseizure activity in mouse models of drug-resistant Dravet and Lennox-Gastaut syndrome.
Epilepsy researchers, families of children with drug-resistant seizures, and anyone interested in cannabinoid-inspired drug development beyond cannabis.
What the researchers found
Magnolol reduced seizures in both Dravet (Scn1a+/-) and Lennox-Gastaut (Gabrb3+/D120N) mouse models and had excellent brain penetration (brain-to-plasma ratio 7.56). Both compounds inhibited T-type calcium channels but had no specific cannabinoid receptor activity.
Why it matters
CBD is already FDA-approved for these epilepsies, but not all patients respond. Finding structurally related compounds from non-cannabis sources that work through different mechanisms (T-type calcium channels rather than CB receptors) could expand treatment options.
The numbers in context
Magnolol brain-to-plasma ratio: 7.56. Honokiol: 3.55. Amorfrutin 2: 0.06. Amorfrutin 2 and magnolol increased seizure threshold in Scn1a+/- mice and reduced hindlimb extension in MES test.
How the study worked
Preclinical study testing three cannabis-like compounds (amorfrutin 2, honokiol, magnolol) in genetic mouse models of Dravet and Lennox-Gastaut syndrome, with pharmacokinetic profiling and molecular pharmacology at CB receptors and T-type calcium channels.
What this study cannot tell us
Mouse epilepsy models don't perfectly replicate human seizure disorders. These are early-stage findings needing extensive development. Magnolol's non-cannabinoid mechanism means it may have different side effect profiles.
How to read the evidence
Well-designed preclinical study using clinically relevant genetic models, but compounds need extensive development before clinical application.
When this study was published
Recent drug discovery study opening new avenues for antiseizure medications inspired by cannabinoid structures.
The bigger picture
Nature contains many cannabinoid-like molecules beyond cannabis. Exploring these structural relatives could yield new antiseizure drugs without the regulatory and social complexities of cannabis-derived medicines.
Questions still open
- Could magnolol be developed into a clinical antiseizure drug? Would combining it with CBD provide additive benefits through complementary mechanisms?
Common questions
Are these compounds found in cannabis?
How do they compare to CBD for epilepsy?
Read the original research
Cannabinoid-like compounds found in non-cannabis plants exhibit antiseizure activity in genetic mouse models of drug-resistant epilepsy.
Epilepsia, 66(1), 303-314
Citation
Yip, Ka Lai; Udoh, Michael; Sharman, Laura A; Harman, Thomas; Bedoya-Pérez, Miguel; Anderson, Lyndsey L; Banister, Samuel D; Arnold, Jonathon C. (2025). Cannabinoid-like compounds found in non-cannabis plants exhibit antiseizure activity in genetic mouse models of drug-resistant epilepsy.. Epilepsia, 66(1), 303-314. https://doi.org/10.1111/epi.18177
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk